Resiniferatoxin

Drug Profile

Resiniferatoxin

Alternative Names: MCP-101; RTX

Latest Information Update: 03 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Analgesics
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 30 Jun 2017 Sorrento Therapeutics plans a phase II trial for Cancer pain in late 2017
  • 29 Jun 2017 Sorrento Therapeutics plans a phase Ib trial for Cancer pain (Epidural injection)
  • 12 Aug 2015 National Institute of Neurological Disorders and Stroke suspends enrolment in a phase I/II trial for Cancer Pain in USA (NCT02522611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top